By InvitationNot Applicable

Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature

United States25 participantsStarted 2025-01-15

Plain-language summary

This is an observational study that includes patients with breast cancer or non-small cell lung cancer who will be treated with immune checkpoint inhibitor (ICI) therapy. The investigators will use echocardiograms, blood draws, and PET stress tests to understand how ICI therapy affects the heart and circulatory system.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ≥18 years of age * Either diagnosis of breast cancer with plan for treatment according to the Keynote 522 regimen or non-small-cell lung cancer planned for neoadjuvant treatment that includes pembrolizumab * Able to provide written informed consent Exclusion Criteria: * Pregnant or breast-feeding: * Prior treatment with ICI therapy. * Vulnerable patients, including pregnant women and prisoners * Absolute Contraindication to rest/vasodilator stress PET/CT

What they're measuring

Incidence of new abnormal myocardial blood flow reserve (MBFR)

Timeframe: 3 months

Trial details

NCT IDNCT06332131

SponsorAbramson Cancer Center at Penn Medicine

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-07

View on ClinicalTrials.gov More Coronary Microvascular Dysfunction trials